Amarin Loses Supreme Court Patent Battle Over Vascepa 'Skinny Label'
AMRN sits 24% above its 52-week low of $11.65.
Summary
The U.S. Supreme Court unanimously ruled against Amarin, siding with generic drugmaker Hikma in a critical 'skinny label' patent dispute over Amarin's cardiovascular drug, Vascepa. This decision overturns a lower court ruling that had favored Amarin. The ruling significantly weakens Amarin's patent protection for Vascepa, which is the company's sole product and generated $213.6 million in revenue in 2025. This outcome could lead to increased generic competition, directly impacting Amarin's future sales and profitability. The ruling follows the Supreme Court hearing arguments on this case, which was reported in late April.
At the time of this announcement, AMRN was trading at $14.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $304.8M. The 52-week trading range was $11.65 to $20.90. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.